What Degarelix is
Degarelix is a GnRH antagonist peptide drug used in approved endocrine-oncology contexts.
Degarelix is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it contrasts with GnRH agonists and shows another important peptide-drug mechanism family.
The useful starting point is to separate the molecule itself from the internet story around it. It contrasts with GnRH agonists and shows another important peptide-drug mechanism family.
Why people keep looking it up
It contrasts with GnRH agonists and shows another important peptide-drug mechanism family.
Degarelix is a GnRH antagonist peptide drug used in approved endocrine-oncology contexts.
Degarelix tends to stay in the conversation because it touches a familiar public theme: gnrh antagonist, hormone suppression, and endocrine medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide antagonist with direct human evidence.
Human trials and official labeling support specific approved uses.
Mechanistic support follows direct GnRH antagonism and endocrine suppression.
Why this page carries the current tier: Approved peptide antagonist with direct human evidence.
The current seed trail for Degarelix is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a serious endocrine medicine and should not be framed like a lifestyle peptide.
FDA-approved degarelix products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Degarelix. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Degarelix is CID 16136245. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16136245
- Formula
- C82H103ClN18O16
- Molecular weight
- 1632.3
- InChIKey
- MEUCPCLKGZSHTA-XYAYPHGZSA-N
Matched synonyms include Degarelix, 214766-78-6, degarelixum, SX0XJI3A11, FE-200486 (free base), DTXSID801026401, FE200486 ANHYDROUS FREE BASE, FE-200486 ANHYDROUS FREE BASE.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Degarelix returns 168 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Degarelix returns 395 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- FIRMAGON
- Generic names
- DEGARELIX
- Routes
- Not linked
- Application numbers
- NDA022201
Indications and usage. 1 INDICATIONS AND USAGE FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Hypersensitivity: Anaphylaxis, urticaria and angioedema have been reported. Discontinue FIRMAGON if a severe hypersensitivity reaction occurs and manage as clinically indicated ( 5.1 ) QT Interval Prolongation: Androgen deprivation therapy treatment with FIRMAGON may prolong the QT interval. ( 5.2 ) Embryo-Fetal Toxicity: FIRMAGON can cause fetal harm. ( 5.4 , 8.1 ) 5.1 Hypersensitivity Re...
Contraindications. 4 CONTRAINDICATIONS FIRMAGON is contraindicated in patients with history of severe hypersensitivity to degarelix or to any of the product components [see Warnings and Precautions (5.1) ] . Patients with history of severe hypersensitivity reactions to degarelix or to any of the product components ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.